I den anden undersøgelse var den progressionsfrie overlevelse 8, 0 måneder hos patienter, der fik placebo, og 9, 4 måneder hos dem, der fik Avastin.
In the second study, progression-free survival was 8.0 months in patients receiving placebo and 9.4 months in those receiving Avastin.